|
Comparison between early and late immunisation with three doses of an heptavalent pneumococcal conjugate vaccine in allogeneic stem cell transplant recipients
This trial is a prospective randomized, multicentric study, designed according to the recommendations for EBMT trials, and supported by Wyeth Lederle. Patients between 5 and 65 years are eligible if they received an allogeneic stem cell transplantation 85 to 109 days before inclusion, and have not experienced S. pneumoniae since transplant. They are randomized to receive 3 injections of Prevenar® at one month intervals, beginning : either on d100 ± 10 (Early Group), or at 9 months ± 10 days (Late Group), followed by one dose of 23 valent polysaccharide (PS23) vaccine administered at 12 and 18 months post-transplant, respectively. The primary endpoint is based on the serum level of antipneumococcal antibodies to the 7 serotypes included in the conjugate vaccine after 3 injections. Fifteen centres from 7 countries participate. The trial has been open since December 2001 in France, and January 2002 in Sweden. It is expected to open in centres in other countries in Spring 2002. An update of this study was presented at EBMT 2005 in Prague.
Prospective
study for the management of hepatitis in stem cell transplant A
survey of CMV retinitis after stem cell transplant A
prospective evaluation of central nervous system complications following
BMT/SCT Cidofovir
therapy for viral infections occurring after stem cell transplant A
study of risk factors for Pneumocystis carinii pneumonia after autologous
stem cell transplant Febrile Neutropenia survey Caspofungin in combination
with other antifungals in children Infections in reduced-intensity
transplants and validation of severity grades
A full list of surveys carried out by the IDWP can be viewed by clicking here. |
